What is B55R1 and B55R2 used for?

B55R1 and B55R2 is indicated for Type 2 diabetes, Heart failure.

Who makes B55R1 and B55R2?

B55R1 and B55R2 is developed by AJU Pharm Co., Ltd..

What development phase is B55R1 and B55R2 in?

B55R1 and B55R2 is FDA-approved (marketed).

What are the side effects of B55R1 and B55R2?

Common side effects include Nausea, Diarrhea, Vomiting, Hypotension, Increased urination.

Last reviewed 2026-04-23 · How we verify

B55R1 and B55R2

AJU Pharm Co., Ltd. · FDA-approved active Small molecule

B55R1 and B55R2 are inhibitors of the sodium-glucose cotransporter 2 (SGLT2).

B55R1 and B55R2 are inhibitors of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes, Heart failure.

At a glance

Generic name	B55R1 and B55R2
Sponsor	AJU Pharm Co., Ltd.
Drug class	SGLT2 inhibitor
Target	SGLT2
Modality	Small molecule
Therapeutic area	Diabetes
Phase	FDA-approved

Mechanism of action

By inhibiting SGLT2, B55R1 and B55R2 reduce glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This action also leads to a mild diuretic effect and a reduction in blood pressure.

Approved indications

Type 2 diabetes
Heart failure

Common side effects

Nausea
Diarrhea
Vomiting
Hypotension
Increased urination

Key clinical trials

To Evaluate the Efficacy and Safety of Combination Therapy With B55R1 and B55R2 Compared to B55R1 Monotherapy in Patients With NPDR (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

B55R1 and B55R2 CI brief — competitive landscape report
B55R1 and B55R2 updates RSS · CI watch RSS
AJU Pharm Co., Ltd. portfolio CI